Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
CYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any severity and serotype, serotype specific efficacy, efficacy dependent on baselin...
| Main Authors: | , |
|---|---|
| Outros Autores: | |
| Formato: | Journal Article |
| Idioma: | English |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://hdl.handle.net/10356/80254 http://hdl.handle.net/10220/40437 |